Vice President, Clinical Development

4DMT to host Investor Day on October 21, 2026. MWN-AI** Summary. 4D Molecular Therapeutics (Nasdaq: FDMT) is set to host an Investor Day on October 21, 2026, in New York City, focusing on its innovative product candidate 4D-150, aimed at revolutionizing the treatment of VEGF-driven retinal diseases. The event will commence at 10:30 AM ET and will feature presentations from 4DMT leadership, alongside a panel discussion with renowned retinal experts, including Dr. Arshad M. Khanani, Dr. Carl C. Awh, Dr. David Eichenbaum, and Dr. Sara J. Haug. These thought leaders are expected to provide valuable insights into the evolving clinical landscape and commercial strategy for 4D-150. 4D-150 is designed to serve as a foundational therapy for blinding retinal vascular diseases, providing sustained delivery of anti-VEGF biologics like aflibercept and anti-VEGF-C through a single intravitreal injection. This innovative approach aims to alleviate the treatment burden associated with frequent bolus injections that currently characterize the management of conditions such as wet age-related macular degeneration and diabetic macular edema, both of which are in Phase 3 clinical trials. In addition to 4D-150, 4D Molecular Therapeutics is advancing its second product candidate, 4D-710, the first known genetic medicine to effectively deliver and express the CFTR transgene in the lungs via aerosol delivery, targeting cystic fibrosis. The company is committed to developing disease-targeted therapeutics with the potential to significantly improve patients' lives. Investors interested in attending the event can register online, with a recorded version of the presentations made available for one year on the company's website. MWN-AI** Analysis. 4D Molecular Therapeutics (Nasdaq: FDMT) is gearing up for an Investor Day on October 21, 2026, where it aims to showcase the progress and future potential of its lead product candidate, 4D-150, designed to address VEGF-driven retinal diseases. With renowned retinal experts participating, this event is an excellent opportunity for investors to gain deeper insights into the company's clinical advancements and commercial strategy. 4D-150 stands out as a transformative biological therapy intended to deliver sustained anti-VEGF treatment through a single intravitreal injection. This innovation has the potential to significantly reduce the treatment burden for diseases such as wet age-related macular degeneration and diabetic macular edema, which are both in pivotal Phase 3 trials. The market for ocular therapeutics is robust, driven by the increasing prevalence of retinal diseases, and a successful outcome from these trials could position 4DMT as a market leader. Investors should pay attention to the expert panel discussions at the Investor Day, as insights from respected figures in ophthalmology could address the anticipated efficacy, safety, and market adoption of 4D-150. This event will allow stakeholders to evaluate the company's long-term vision and competitive positioning in a rapidly evolving biopharmaceutical marketplace. As of now, 4DMT represents a high-risk, high-reward investment given its therapeutic candidates are still undergoing clinical evaluation and have not received FDA approval. Investors should closely monitor the outcomes of the Phase 3 trials and responses during the Q&A to gauge potential market success. Overall, if clinical results are favorable, 4DMT could experience substantial growth, making it a compelling watch over the upcoming months. **MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release. October 05, 2026 08:00:00 am * Company to share insights on the advancing clinical profile and commercial vision for 4D-150 * Renowned retinal experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Carl C. Awh, MD, FASRS; Dr. David Eichenbaum, MD, FASRS; and Dr. Sara J. Haug, MD, PhD, will join 4DMT leadership to offer perspective on transforming the treatment paradigm in VEGF-driven retinal diseases * Live event will take place in New York City on October 21, 2026 at 10:30am ET EMERYVILLE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the Company will host an Investor Day on Wednesday, October 21, 2026, in New York City. The live event will begin at 10:30am ET and include a Company presentation, KOL panel discussions and a live Q&A session. An archived copy of the webcast will be available for up to one year on the "Investors" section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events. About 4DMT 4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company's lead product candidate, 4D-150, is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company's lead indication for 4D-150 is wet age-related macular degeneration and the second indication is diabetic macular edema, which are both in Phase 3 development. The Company's second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics(TM), 4DMT(TM), Therapeutic Vector Evolution(TM), Backbone 4 Retina(TM) and the 4DMT logo are trademarks of 4DMT. All of its product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of its product candidates for the therapeutic uses for which they are being studied. Media: Jenn Gordon dna Communications [email protected] Investors: Julian Pei Head of Investor Relations and Strategic Finance [email protected] FAQ**. How does 4D Molecular Therapeutics Inc. (FDMT) plan to differentiate the multi-year sustained delivery system of 4D-150 from traditional treatment approaches in the management of VEGF-driven retinal diseases? 4D Molecular Therapeutics Inc. plans to differentiate 4D-150 by utilizing a multi-year sustained delivery system that targets the root causes of VEGF-driven retinal diseases, potentially reducing the frequency of treatments compared to traditional approaches. What insights do the renowned retinal experts believe will most significantly influence the commercial vision for 4D Molecular Therapeutics Inc. (FDMT) in the years following the launch of 4D-150? Renowned retinal experts believe advancements in targeted gene therapy and innovative delivery systems will significantly influence the commercial vision for 4D Molecular Therapeutics Inc. (FDMT) post-launch of 4D-150, enhancing treatment outcomes and market potential. Can you elaborate on any potential collaborations or partnerships 4D Molecular Therapeutics Inc. (FDMT) is pursuing to enhance the market launch strategy of 4D-150 in treating wet age-related macular degeneration and diabetic macular edema? As of now, specific details on collaborations or partnerships that 4D Molecular Therapeutics Inc. (FDMT) is pursuing for 4D-150's market launch strategy in treating wet age-related macular degeneration and diabetic macular edema have not been publicly disclosed. What key strategies will Molecular Therapeutics Inc. (FDMT) employ to educate physicians and patients about the benefits of reduced treatment burden associated with 4D-150 compared to current bolus injections? 4D Molecular Therapeutics Inc. will implement targeted educational campaigns, utilize digital platforms for information dissemination, conduct physician training sessions, and share patient testimonials to highlight the benefits of 4D-150 over traditional bolus injections. **MWN-AI FAQ is based on asking OpenAI questions about 4D Molecular Therapeutics Inc. (NASDAQ: FDMT).

4D Molecular Therapeutics (NASDAQ:FDMT) announces quarterly earnings results. August 13, 2026 Key points. * 4D Molecular Therapeutics missed earnings expectations: The company reported a quarterly loss of $1.04 per share versus the $1.02 consensus estimate, while revenue of $3.78 million exceeded expectations of $3.62 million. * Shares fell 1.9% to $11.65 after the results. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $29.75, although ratings range from "Strong Buy" to "Sell." * Insiders sold 197,226 shares worth approximately $2.2 million over the past 90 days, while institutional investors own 99.27% of the company's stock. * Five stocks we like better than 4D Molecular Therapeutics. 4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02), FiscalAI reports. 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The firm had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics stock down 1.9%. NASDAQ:FDMT traded down $0.22 during midday trading on Thursday, hitting $11.65. The stock had a trading volume of 705,798 shares, compared to its average volume of 787,133. 4D Molecular Therapeutics has a one year low of $5.97 and a one year high of $14.00. The company has a market capitalization of $609.06 million, a price-to-earnings ratio of -4.53 and a beta of 2.73. The stock has a 50-day moving average of $10.84 and a 200 day moving average of $9.83. Analyst ratings changes. FDMT has been the subject of a number of recent analyst reports. Chardan Capital raised shares of 4D Molecular Therapeutics to a "strong-buy" rating in a research note on Tuesday, July 28th. Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. HC Wainwright restated a "buy" rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Wall Street Zen downgraded 4D Molecular Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. Finally, B. Riley Financial initiated coverage on 4D Molecular Therapeutics in a report on Friday, July 31st. They set a "buy" rating and a $37.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $29.75. Insiders place their bets. In other 4D Molecular Therapeutics news, insider Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the sale, the insider directly owned 8,617 shares of the company's stock, valued at $103,404. The trade was a 53.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Kirn sold 12,415 shares of the company's stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $10.05, for a total value of $124,770.75. Following the completion of the sale, the insider owned 871,737 shares of the company's stock, valued at $8,760,956.85. This represents a 1.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 197,226 shares of company stock valued at $2,200,677. 7.90% of the stock is currently owned by corporate insiders. Institutional inflows and outflows. Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Martingale Asset Management L P lifted its holdings in 4D Molecular Therapeutics by 12.4% during the fourth quarter. Martingale Asset Management L P now owns 11,775 shares of the company's stock worth $88,000 after buying an additional 1,303 shares during the period. Commonwealth Equity Services LLC purchased a new position in shares of 4D Molecular Therapeutics in the 4th quarter valued at $150,000. Brevan Howard Capital Management LP purchased a new position in shares of 4D Molecular Therapeutics in the 3rd quarter valued at $143,000. ADAR1 Capital Management LLC bought a new position in shares of 4D Molecular Therapeutics in the 3rd quarter worth $145,000. Finally, Bridgeway Capital Management LLC lifted its stake in shares of 4D Molecular Therapeutics by 100.3% during the 2nd quarter. Bridgeway Capital Management LLC now owns 25,000 shares of the company's stock worth $93,000 after purchasing an additional 12,516 shares during the last quarter. 99.27% of the stock is currently owned by institutional investors. 4D Molecular Therapeutics company profile. 4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches. 4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider 4D Molecular Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list. While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.